In this sense, the ISAR REACT I study was published where more than 2,000 low cardiovascular risk patients underwent PCI, and were all treated with 600mg of clopidogrel at least six hours before the procedure. They did not benefit from the addition of abciximab to the association of ASA and clopidogrel, which is the standard therapy in current clinical practice.
En este sentido, se publicó el estudio ISAR REACT I, en el que se sometieron a ICP a más de dos mil pacientes de bajo riesgo cardiovascular -todos previamente tratados con 600mg de clopidogrel, al menos seis horas antes del procedimiento-, sin demostrarse beneficio de la adición de abciximab a la asociación de AAS y clopidogrel, terapia estándar de la práctica clínica actual.
O resultado final dessa análise sugere fortemente não haver mais papel para os IG IIb/IIIa em angioplastias eletivas de baixo risco.